Miguel Villanueva, MD
@tackle18.bsky.social
Interés en comprender, compartir y aprender.
Hemato-Oncología 🦀, Terapia Celular, Enfermedades Infecciosas 🦠, Medicina de Precisión 🧬
Cuenta PERSONAL, mis opiniones son eso: mías
Maradoniano
Hemato-Oncología 🦀, Terapia Celular, Enfermedades Infecciosas 🦠, Medicina de Precisión 🧬
Cuenta PERSONAL, mis opiniones son eso: mías
Maradoniano
Reposted by Miguel Villanueva, MD
Immune alterations in myeloma evolution and outcomes: quo vadis? buff.ly/6ft0xTG #hemesky
September 3, 2025 at 4:04 PM
Immune alterations in myeloma evolution and outcomes: quo vadis? buff.ly/6ft0xTG #hemesky
Reposted by Miguel Villanueva, MD
A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR T-cell therapy. Read the full case details: nej.md/41fYX4v
#MedSky #Hematology #Genetics
#MedSky #Hematology #Genetics
September 1, 2025 at 7:02 PM
A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR T-cell therapy. Read the full case details: nej.md/41fYX4v
#MedSky #Hematology #Genetics
#MedSky #Hematology #Genetics
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet www.thelancet.com/journals/lan...
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating
relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially
restricted by complex m...
www.thelancet.com
August 8, 2025 at 3:18 PM
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet www.thelancet.com/journals/lan...
Reposted by Miguel Villanueva, MD
July 9, 2025 at 5:04 PM
Reposted by Miguel Villanueva, MD
In this 60-Second Journal Club, NEJM Editorial Fellow Abarna Pearl, MD, MPH, summarizes the BALANCE trial comparing antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. Read the full article and accompanying Research Summary: nej.md/3Z5bTJD
#MedSky #IDSky
#MedSky #IDSky
July 9, 2025 at 5:11 PM
In this 60-Second Journal Club, NEJM Editorial Fellow Abarna Pearl, MD, MPH, summarizes the BALANCE trial comparing antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. Read the full article and accompanying Research Summary: nej.md/3Z5bTJD
#MedSky #IDSky
#MedSky #IDSky
Reposted by Miguel Villanueva, MD
Perforin is responsible for creating a channel/pore (punching a hole) between cytolytic lymphocytes, natural killer cells and CD8 T cells, and their target cells, allowing for the delivery of apoptosis-inducing granzyme proteins. buff.ly/YFitped #hemesky
June 24, 2025 at 5:04 PM
Perforin is responsible for creating a channel/pore (punching a hole) between cytolytic lymphocytes, natural killer cells and CD8 T cells, and their target cells, allowing for the delivery of apoptosis-inducing granzyme proteins. buff.ly/YFitped #hemesky
Reposted by Miguel Villanueva, MD
EHA Highlights: First-in-Human Study of Trispecific Antibody JNJ-5322 Shows Promising Activity in Relapsed/Refractory Multiple Myeloma
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA #EHA2025 #MM #RRMM
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA #EHA2025 #MM #RRMM
EHA 2025 Highlights: JNJ-5322 Trispecific Antibody in RRMM
EHA 2025 highlights first-in-human results of JNJ-5322, a trispecific antibody with 100% ORR in naïve RRMM patients and favorable safety profile.
oncodaily.com
June 18, 2025 at 5:11 PM
Reposted by Miguel Villanueva, MD
Risk of SMN Low After CAR-T Therapy: The risk of secondary #myeloid #neoplasms (SMNs) following #CD19 #CARTcell therapy may be lower than expected. According to a retrospective study, SMNs occurred in 2.5% of patients after treatment with CAR T-cell therapy.
#HemeSky
#HemeSky
May 15, 2025 at 3:08 PM
Risk of SMN Low After CAR-T Therapy: The risk of secondary #myeloid #neoplasms (SMNs) following #CD19 #CARTcell therapy may be lower than expected. According to a retrospective study, SMNs occurred in 2.5% of patients after treatment with CAR T-cell therapy.
#HemeSky
#HemeSky
Reposted by Miguel Villanueva, MD
For patients undergoing CD19-directed #CARTcell therapy, #itacitinib prophylaxis effectively reduced the incidence and severity of #cytokine release syndrome (CRS), with just 17.4% of patients experiencing grade ≥2 CRS compared with 56.5% on placebo: ow.ly/9y5l50W4mYU
#HemeSky #MedSky
#HemeSky #MedSky
Itacitinib Prophylaxis Reduces the Incidence of CRS, ICANS in IEC Therapy | ASH Clinical News | American Society of Hematology
ow.ly
June 5, 2025 at 3:42 PM
For patients undergoing CD19-directed #CARTcell therapy, #itacitinib prophylaxis effectively reduced the incidence and severity of #cytokine release syndrome (CRS), with just 17.4% of patients experiencing grade ≥2 CRS compared with 56.5% on placebo: ow.ly/9y5l50W4mYU
#HemeSky #MedSky
#HemeSky #MedSky
Reposted by Miguel Villanueva, MD
Results from an MD Anderson study identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 CAR T cell therapy.
How the findings offer insights on the best potential clinical pathways: spr.ly/60174rfXF #EndCancer
How the findings offer insights on the best potential clinical pathways: spr.ly/60174rfXF #EndCancer
Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
spr.ly
June 18, 2025 at 4:39 PM
Results from an MD Anderson study identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 CAR T cell therapy.
How the findings offer insights on the best potential clinical pathways: spr.ly/60174rfXF #EndCancer
How the findings offer insights on the best potential clinical pathways: spr.ly/60174rfXF #EndCancer
Reposted by Miguel Villanueva, MD
A recent meta-analysis in JAMA Network Open evaluated cardiovascular risks in 1,528 adults receiving CAR T-cell therapy for advanced blood cancers.
@jama.com
#Onco404 #Cancer #Kanser #Hematology #CardioOncology #CARTCellTherapy #MetaAnalysis #MedResearch #MedSky #OncSky
@jama.com
#Onco404 #Cancer #Kanser #Hematology #CardioOncology #CARTCellTherapy #MetaAnalysis #MedResearch #MedSky #OncSky
April 28, 2025 at 10:33 AM
A recent meta-analysis in JAMA Network Open evaluated cardiovascular risks in 1,528 adults receiving CAR T-cell therapy for advanced blood cancers.
@jama.com
#Onco404 #Cancer #Kanser #Hematology #CardioOncology #CARTCellTherapy #MetaAnalysis #MedResearch #MedSky #OncSky
@jama.com
#Onco404 #Cancer #Kanser #Hematology #CardioOncology #CARTCellTherapy #MetaAnalysis #MedResearch #MedSky #OncSky
Reposted by Miguel Villanueva, MD
There are so many ways to rev up our immune response against cancer. Here, the oncolytic viruses
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
March 27, 2025 at 3:30 PM
There are so many ways to rev up our immune response against cancer. Here, the oncolytic viruses
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
Reposted by Miguel Villanueva, MD
In the BALANCE trial, patients with bacteremia were assigned to 7 or 14 days of appropriate antimicrobial therapy, and 7 days of therapy was found to be noninferior to 14 days. Full trial results and Research Summary: nej.md/3Z5bTJD
#MedSky #CriticalCare #IDSky
#MedSky #CriticalCare #IDSky
March 25, 2025 at 1:36 PM
In the BALANCE trial, patients with bacteremia were assigned to 7 or 14 days of appropriate antimicrobial therapy, and 7 days of therapy was found to be noninferior to 14 days. Full trial results and Research Summary: nej.md/3Z5bTJD
#MedSky #CriticalCare #IDSky
#MedSky #CriticalCare #IDSky
Reposted by Miguel Villanueva, MD
Today is World TB day. Here's a recent comprehensive review on therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
www.nature.com/articles/s41...
rdcu.be/eeQ0m
www.nature.com/articles/s41...
rdcu.be/eeQ0m
March 24, 2025 at 2:14 PM
Today is World TB day. Here's a recent comprehensive review on therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
www.nature.com/articles/s41...
rdcu.be/eeQ0m
www.nature.com/articles/s41...
rdcu.be/eeQ0m
Come together, really hard times for the science. | Science www.science.org/doi/10.1126/...
Come together, right now
The chaos, conflicting information, firings, and hurtful rhetoric of the Trump administration’s approach to science over the past month are causing anxiety, grief, and concern for the scientific commu...
www.science.org
February 25, 2025 at 5:02 PM
Come together, really hard times for the science. | Science www.science.org/doi/10.1126/...
Restoration of the #immune function as a complementary strategy to treat #CLL effectively. This approach aims to achieve dual disease control by targeting both malignant B-cell activity and the often-compromised immune system in #CLL patients.
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively #Ibrutinib #MECFS #LongCovid
jeccr.biomedcentral.com/articles/10....
jeccr.biomedcentral.com/articles/10....
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively - Journal of Experimental & Clinical Cancer Research
Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by uncontrolled proliferation of B-cells and severe immune dysfunction. Chemo(immuno)therapies (CIT) have traditionally a...
jeccr.biomedcentral.com
February 15, 2025 at 10:33 AM
Reposted by Miguel Villanueva, MD
Hematopoietic stem cell transplant is a critical treatment for various cancers and other conditions.
This JAMA Insights discusses the process of allogeneic stem cell donation, including donor selection, preparation, and potential risks and benefits.
ja.ma/40911K8
This JAMA Insights discusses the process of allogeneic stem cell donation, including donor selection, preparation, and potential risks and benefits.
ja.ma/40911K8
January 7, 2025 at 8:15 PM
Hematopoietic stem cell transplant is a critical treatment for various cancers and other conditions.
This JAMA Insights discusses the process of allogeneic stem cell donation, including donor selection, preparation, and potential risks and benefits.
ja.ma/40911K8
This JAMA Insights discusses the process of allogeneic stem cell donation, including donor selection, preparation, and potential risks and benefits.
ja.ma/40911K8
Reposted by Miguel Villanueva, MD
Cytomegalovirus (CMV) is the leading cause of infectious birth defects and linked to many other morbidities such as with transplantation. For the first time after >50 years of pursuit, a vaccine is in reach jci.org/articles/vie...
January 5, 2025 at 4:14 PM
Cytomegalovirus (CMV) is the leading cause of infectious birth defects and linked to many other morbidities such as with transplantation. For the first time after >50 years of pursuit, a vaccine is in reach jci.org/articles/vie...
Del gran Bukowski "No leaders please" Esto de las fechas "especiales" si tienen algo de bueno (probablemente lo único) es que son recordatorio de gratitud, reflexión, y sobre todo, de re invención a diferentes niveles, al no tenerlo en cuenta todo pierde sentido...
youtu.be/PLauo0Qx48k?...
youtu.be/PLauo0Qx48k?...
It Is Your Life - a Charles Bukowski Poem
YouTube video by Willem Martinot
youtu.be
December 31, 2024 at 8:19 AM
Del gran Bukowski "No leaders please" Esto de las fechas "especiales" si tienen algo de bueno (probablemente lo único) es que son recordatorio de gratitud, reflexión, y sobre todo, de re invención a diferentes niveles, al no tenerlo en cuenta todo pierde sentido...
youtu.be/PLauo0Qx48k?...
youtu.be/PLauo0Qx48k?...
Un documental desgarrador, extraordinario #NoOtherLand. Siempre en @filmin.es
Este es el retrato devastador de toda una comunidad que está siendo destrozada a manos del ejército israelí y, a la vez, una bella historia de amistad.
#NoOtherLand es el documental del año. El más relevante y el más importante. Ganó en los #EuropeanFilmAwards y apunta al Óscar.
#NoOtherLand es el documental del año. El más relevante y el más importante. Ganó en los #EuropeanFilmAwards y apunta al Óscar.
December 25, 2024 at 11:36 PM
Un documental desgarrador, extraordinario #NoOtherLand. Siempre en @filmin.es
La contaminación mata. #AirPollution
New in @bloodportfolio.bsky.social: People exposed to higher concentrations of 3 types of air pollution had a higher risk of hospitalization for a #bloodclot compared w/those exposed to lower concentrations: bit.ly/408cHON
#hematology #HemeSky #Bloodsky #VTE
#hematology #HemeSky #Bloodsky #VTE
December 17, 2024 at 7:01 PM
La contaminación mata. #AirPollution
Reposted by Miguel Villanueva, MD
JAMA Clinical Guidelines Synopsis summarizes the 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. https://ja.ma/4guePp2
December 14, 2024 at 1:00 PM
JAMA Clinical Guidelines Synopsis summarizes the 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. https://ja.ma/4guePp2
CAR T-cell therapy has demonstrated efficacy in treating hematologic malignancies and improving overall survival for patients with large B-cell lymphoma. This Review describes approved indications, clinical outcomes, and emerging applications.
https://ja.ma/3ZKhTrO
https://ja.ma/3ZKhTrO
December 13, 2024 at 9:40 AM
Reposted by Miguel Villanueva, MD
Allogeneic stem cell transplant can be a life-saving therapy for pts w cancer or other conditions such as sickle cell disease. JAMA Fellow Hermioni Amonoo, harvardmed, joins JAMA Deputy Editor Kristin Walter to discuss allogeneic stem cell donation.
https://ja.ma/41tyj9b
https://ja.ma/41tyj9b
December 12, 2024 at 11:00 AM
Allogeneic stem cell transplant can be a life-saving therapy for pts w cancer or other conditions such as sickle cell disease. JAMA Fellow Hermioni Amonoo, harvardmed, joins JAMA Deputy Editor Kristin Walter to discuss allogeneic stem cell donation.
https://ja.ma/41tyj9b
https://ja.ma/41tyj9b